Skip to main content

Janus Kinase Inhibitors for Severe Alopecia Areata: A Systematic Literature Review and Network Meta-Analysis

In brief

Upadacitinib 30 mg leads indirect comparison, with 54% reaching hair regrowth target

In an indirect comparison of seven trials involving 3,739 people with severe alopecia areata, an estimated 54% taking upadacitinib 30 mg reached a Severity of Alopecia Tool score of 20 or less after 24 weeks, the highest rate among treatments studied. There were no head-to-head trials, so direct comparisons are still needed to confirm which treatment works best.

Journal
The Journal of investigative dermatology (Q1)
Published
10 November 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Arash Mostaghimi, Ahmed M Soliman, Benjamin Ungar, Sergio Vaño-Galvan, Jonathan J Woolley, Kristen Westerhoff, et al.
PMID
43008966
DOI
10.1016/j.jid.2026.10.039

Why clinicians should know about it

  • Picked for Dermatology (top studies of the week, 15 November 2026): Systematic comparison of targeted JAK inhibitors for severe alopecia areata

Abstract

Although multiple Janus kinase inhibitors (JAKi) are available for alopecia areata (AA), lack of head-to-head studies complicates treatment selection. This analysis indirectly compared oral JAKi efficacy for severe AA at weeks 12 and 24, including FDA-approved treatments and upadacitinib, using a systematic literature review and phase 3 upadacitinib trial data. Phase 3 or 4 randomized trials of patients with severe AA (Severity of Alopecia Tool [SALT] score ≥50) evaluating baricitinib (2mg [BARI2mg], 4mg [BARI4mg] once daily [QD]), ritlecitinib (50mg [RIT50mg] QD), deuruxolitinib (8mg [DEUR8mg] twice daily) and upadacitinib (15mg [UPA15mg], 30mg [UPA30mg] QD) were eligible; 7 studies were analyzed. Bayesian network meta-analyses (NMAs) evaluated hair regrowth measures. Response rates were estimated from risk differences. Significance was evaluated as 95% credible intervals of risk differences excluding 0. Analyzing 3739 patients, estimated probabilities of achieving SALT score ≤20 at week 24 were highest with UPA30mg (54.2% [95% credible interval: 49.5-58.7]), followed by UPA15mg (44.5%[39.8-49.1]), DEUR8mg (30.1%[26.1-34.0]), BARI4mg (27.6%[22.9-32.1]), RIT50mg (22.9%[15.7-30.9]), BARI2mg (11.1%[6.9-15.5]), and placebo (2.5%[1.6-3.5]); rates were significantly higher with JAKi vs placebo, and UPA30mg vs other treatments. NMAs estimate UPA30mg may have the highest probability of supporting hair regrowth in severe AA at week 24, followed by UPA15mg, DEUR8mg, BARI4mg, RIT50mg, and BARI2mg.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.